|1.||Baraldi, Pier Giovanni: 3 articles (05/2004 - 03/2003)|
|2.||Romagnoli, Romeo: 3 articles (05/2004 - 03/2003)|
|3.||Perrella, Mark A: 2 articles (01/2010 - 09/2004)|
|4.||Macias, Alvaro A: 2 articles (01/2010 - 09/2004)|
|5.||Baron, Rebecca M: 2 articles (01/2010 - 09/2004)|
|6.||Layne, Matthew D: 2 articles (01/2010 - 09/2004)|
|7.||Marchini, Sergio: 2 articles (05/2004 - 01/2004)|
|8.||Beria, Italo: 2 articles (05/2004 - 03/2003)|
|9.||Cozzi, Paolo: 2 articles (05/2004 - 03/2003)|
|10.||Geroni, Cristina: 2 articles (05/2004 - 01/2004)|
01/01/2011 - "These results demonstrate that peptide-distamycin conjugates are a promising tool to obtain compounds that bind the E2 target DNA-sequences with remarkable affinity and suggest that a bipartite major/minor groove binding scaffold can be a useful approach for therapeutic treatment of HPV infection."
01/01/1964 - "THERAPEUTIC ACTION OF DISTAMYCIN A ON VACCINIA VIRUS INFECTIONS IN VIVO."
11/01/1977 - "In contrast to distamycin A analogue VII had an inhibitory effect on influenza infection in chick embryos."
08/15/2015 - "Liposomes containing Distamycin A (DA) may be clinically useful in the treatment of ocular HSV infections, especially in acyclovir-resistant HSV keratitis. "
11/15/1992 - "Characterization of the toxicity of distamycin derivatives on cancer cell lines and rat heart."
09/01/1988 - "Distamycin A-inducible fragile sites and cancer proneness."
07/01/1986 - "This fragile site, which is known to be a cancer breakpoint, has not been reported so far either to be familial or to be inducible by distamycin A. "
12/01/1997 - "Inhibition of growth factor mitogenicity and growth of tumor cell xenografts by a sulfonated distamycin A derivative."
09/01/1992 - "The overall frequency of distamycin A-inducible fragile sites in azoospermia patients appeared to be higher than those reported for Japanese healthy subjects and cancer patients. "
|4.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
02/01/1997 - "1. The purpose of this study was to investigate the antiproliferative effect and the modulation of the mitogenic insulin-like growth factor-I (IGF-I) system by FCE 26644 and FCE 27784, two polyanionic sulphonated distamycin A derivative compounds, on two human non-small cell lung cancer (N-SCLC) cell lines. "
09/15/2004 - "Reduction of nitric oxide synthase 2 expression by distamycin A improves survival from endotoxemia."
01/01/2010 - "Distamycin A inhibits HMGA1-binding to the P-selectin promoter and attenuates lung and liver inflammation during murine endotoxemia."
09/15/2004 - "NO synthase 2 (NOS2) plays an important role in endotoxemia through overproduction of NO. Distamycin A (Dist A) belongs to a class of drugs termed minor-groove DNA binders, which can inhibit transcription factor binding to AT-rich regions of DNA. "
|1.||DNA (Deoxyribonucleic Acid)
|6.||Intercellular Signaling Peptides and Proteins (Growth Factors)
|7.||Insulin-Like Growth Factor I (IGF-1)
|8.||HLA-DR Antigens (HLA-DR)
|1.||Heterologous Transplantation (Xenotransplantation)